HomeGeneticsConditionCLN4 disease
Back to Condition
CLN4 disease
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

CLN4 Disease

CLN4 disease is a rare, progressive neurological disorder that primarily affects movement and intellectual function, typically appearing around age 30.

Overview

CLN4 disease is a condition that primarily affects the nervous system, causing problems with movement and intellectual function that worsen over time. The signs and symptoms of this disorder typically appear around age 30, but they can develop anytime between adolescence and late adulthood. Affected individuals usually survive about 15 years after the onset of the disorder.

CLN4 disease is one of a group of disorders known as neuronal ceroid lipofuscinoses (NCLs), which may also be collectively referred to as Batten disease. The adult forms of NCLs, which include CLN4 disease, are sometimes known as Kufs disease. All NCLs affect the nervous system and typically cause worsening problems with vision, movement, and thinking ability. The different NCLs are distinguished by their genetic cause, with each type designated by "CLN" (meaning ceroid lipofuscinosis, neuronal) followed by a number indicating its subtype.

Frequency

CLN4 disease is a rare disorder, but its exact prevalence is unknown. Collectively, all forms of NCL affect an estimated 1 in 100,000 individuals worldwide.

Symptoms

People with CLN4 disease experience a progressive decline in neurological and motor functions. Common symptoms include:

  • Seizures and uncontrollable muscle jerks (myoclonic epilepsy)
  • A decline in intellectual function (dementia)
  • Problems with coordination and balance (ataxia)
  • Tremors or other involuntary movements (motor tics)
  • Speech difficulties (dysarthria)

Causes & Genetic Factors

Mutations in the DNAJC5 gene cause CLN4 disease. This gene provides instructions for making a protein called cysteine string protein alpha (CSPα). In the brain, CSPα plays a role in helping nerve cells communicate with each other by recycling certain proteins involved in nerve impulse transmission, refolding misshapen proteins so they can be reused.

Mutations in the DNAJC5 gene lead to an altered CSPα protein that cannot perform its function. This reduces protein recycling, causing a shortage of functional proteins needed for impulse transmission. Without normal communication between nerve cells, neurological functions are impaired.

Like other NCLs, CLN4 disease is characterized by the accumulation of proteins and other substances in lysosomes, which are cellular compartments that digest and recycle materials. These accumulations occur in cells throughout the body, but nerve cells seem particularly vulnerable to their effects. The buildup can cause cell damage and progressive cell death in the brain and other tissues, contributing to the decline of neurological function. However, it remains unclear how mutations in the DNAJC5 gene lead to this lysosomal buildup.

Inheritance

This condition is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder.

Some cases result from new (de novo) mutations in the gene that occur during the formation of reproductive cells (eggs or sperm) in an affected individual’s parent or during early embryonic development. These cases occur in people with no history of the disorder in their family.

Other Names for This Condition

  • Adult neuronal ceroid lipofuscinosis
  • Ceroid lipofuscinosis, neuronal, 4B, autosomal dominant
  • CLN4B
  • Parry disease

Frequently Asked Questions

What are the typical first symptoms of CLN4 disease, and how does the condition usually progress after onset?::CLN4 disease typically begins around age 30, though it can appear earlier or later. Initial symptoms often include problems with coordination and balance (ataxia), tremors, or other involuntary movements. As the disease progresses, individuals experience a decline in intellectual function (dementia), speech difficulties (dysarthria), and may develop seizures or uncontrollable muscle jerks (myoclonic epilepsy). The neurological decline is progressive, leading to significant impairment over approximately 15 years after symptom onset.
How is CLN4 disease diagnosed, especially since its symptoms can overlap with other neurological disorders?::Diagnosis of CLN4 disease often involves a combination of clinical evaluation, neurological examination, and genetic testing. Given the overlap with other adult-onset neurological conditions, a definitive diagnosis typically relies on identifying specific mutations in the DNAJC5 gene. Brain imaging (MRI) and electroencephalography (EEG) may also be used to assess brain changes and seizure activity, supporting the clinical picture.
re there any specific treatments or therapies available to slow the progression of CLN4 disease or manage its symptoms?::Currently, there is no cure for CLN4 disease, and no specific treatments are known to halt or reverse its progression. Management focuses on supportive care to alleviate symptoms and improve quality of life. This can include medications to control seizures and myoclonus, physical therapy to help with movement and balance, occupational therapy for daily living activities, and speech therapy for communication difficulties. Research into potential therapies is ongoing.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab

Sök
Om ossVillkor och policyVanliga frågorKontakta oss